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hThis review summarizes important advances that took place
during the last year in the field of atherothrombotic disease.
Papers were selected based on relevance, novelty, and
scientific quality. Because of space limitations, when several
publications reported similar findings, a representative study
was included. The paper is divided into 4 distinct sections:
epidemiology, mechanisms of disease, early detection and
risk stratification, and prevention and treatment. The main
highlights of this review are summarized in Table 1.
Epidemiology
A study from Canada confirmed that improved risk factor
profiles account for approximately 50% of recent reductions
in coronary heart disease (CHD) age-adjusted mortality (1).
According to the National Health and Nutrition Examina-
tion Surveys (NHANES), blood pressure control in the last
decade has improved to approximately 50% of the U.S.
population with known hypertension (2). Similarly, data
from NHANES expanding over 30 years reported improve-
ments in total and low-density lipoprotein (LDL) choles-
terol concentrations in U.S. adults (3). It was nonetheless
estimated that approximately one-half of the patients
receiving statins could benefit from therapies targeting
other lipid abnormalities, particularly low high-density
lipoprotein (HDL) cholesterol concentration (4). Unfor-
tunately, in the past 30 years, the prevalence of obesity
doubled, accompanied by increases in triglyceride levels
(3). Moreover, assuming maintenance of current trends,
it was estimated that average U.S. life expectancy in-
creases of approximately 0.3 years associated with smok-
ing decline will be offset by mean reductions in 1 year due
to growing obesity (5). The importance of obesity during
childhood and adolescence was highlighted in a report
that linked its presence to the development of adult
metabolic syndrome, type 2 diabetes mellitus, and sub-
clinical atherosclerosis (6). On a positive note, the
increasing obesity rate appears slower during the past
decade for adults (7) and particularly for children (8).
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2011, accepted March 29, 2011.Data from the multinational REACH (Reduction of
therothrombosis for Continued Health Registry) reported
he contemporary 4-year rates of major cardiovascular
vents among patients with high risk for or established
therothrombosis (Fig. 1). Independent predictors of events
ere polyvascular disease (hazard ratio [HR]: 1.99), an
schemic event in the previous year (HR: 1.71), and the
resence of diabetes (HR: 1.44; p  0.001 for all) (9).
lthough these and other risk factors are consistent
hroughout different world regions, the same registry
dentified a direct relationship between educational level
nd atherothrombotic events in low- to middle-income
ountries, the opposite of that observed in high-income
egions (10). This finding may reflect higher access to a
esternized lifestyle with higher education in developing
ountries, leading to an impaired risk factor profile. The
nstitute of Medicine released recommendations to ad-
ress the “epidemic” of cardiovascular disease in the
eveloping world and promote cardiovascular health
orldwide (11).
echanisms of Disease
he role of mechanical forces on atherogenesis was revisited
n 2010. Computational fluid dynamics evaluated with
oronary intravascular ultrasound (IVUS) in experimental
therosclerosis or carotid magnetic resonance imaging in
atients provided further evidence of the role of reduced
hear stress not only in plaque formation but also in its
rogression (12,13). Conversely, high wall stress at the
houlder of abdominal aneurysms in humans was found to
redict more rapid expansion (14).
Regarding inflammation and atherogenesis, monocytes
nd T-lymphocytes are known to be important in plaque
evelopment. Experimental and clinical studies suggested
n additional contribution of neutrophils to early lesion
ormation and plaque vulnerability (15,16). Both systemic
nd intraplaque markers of inflammation were associated
ith symptomatic stroke and features of plaque vulnerability
17). In addition, associations were described between
eriodontitis, low-grade inflammation, and cardiovascular
vents (18). Moreover, addressing the interplay between
besity, inflammation, and vascular disease, a provoking
ypothesis came from a smaller study involving 71 obese
ubjects that proposed obstructive sleep apnea, rather than
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Year in Atherothrombosis August 16, 2011:779–91obesity, as the main determinant of vascular inflammation
and endothelial dysfunction (19).
Further evidence of the role of plaque neovascularization
in the development of intraplaque hemorrhage came from
an autopsy study that demonstrated correlations between
vessel density and concentrations of intraplaque iron and
erythrocyte fragments. Neovessel density was higher in
nonstenotic segments and stenotic noncalcified plaques than
in normal segments or calcified lesions (Fig. 2) (20).
Moreover, the presence of extensive plaque neovasculariza-
tion and, particularly, intraplaque hemorrhage in carotid
endarterectomy specimens were associated with respective
multiadjusted hazard ratios of 2.2 (95% confidence interval
[CI]: 1.2 to 3.8) and 1.5 (95% CI: 1.1 to 2.2) of subsequent
cardiovascular events such as death, stroke, or myocardial
infarction after a mean follow-up of 2.3 years (21), probably
Figure 1 Current Prognosis in Atherothrombosis
Cumulative incidence curves for the combined cardiovascular (CV) death, myocard
based on presence or absence of prior disease. Reproduced, with permission, fro
Highlights of the Year in AtherothrombosisTable 1 Highlights of the Year in Atherothrombosis
The benefits of reduced smoking, hypertension, and dyslipidemia over the past deca
Carotid plaque neovascularization and intraplaque hemorrhage were associated wit
Measurement of conventional risk factors remains the only Class I indication for risk
C-reactive protein, brain natriuretic peptides, and troponin remain the most clinically
Coronary calcium scoring improved risk classification in 25% of subjects in MESA (6
The enormous potential public health impact of various societal interventions to imp
Tighter blood pressure and glycemic control in type 2 diabetes were not associated
Ticagrelor demonstrated greater platelet inhibition and improved outcomes in comp
In multivessel, stable coronary heart disease, surgery outperformed percutaneous a
Surgery performed as good as or better than stenting in the treatment of carotid orreflecting increased vulnerability not only locally but also
systemically.
Finally, investigations addressed the differences between
eroded and ruptured symptomatic plaques. In a series of 111
sudden cardiac death victims, plaque ruptures occurred in
regions with higher plaque burden and inflammation, whereas
erosions were associated with lower degrees of stenosis and
more advanced thrombus healing, possibly leading to poor
outcome through distal microembolization (22). Additionally,
ystemic and local intrathrombus levels of myeloperoxidase
ere proposed as important players in thrombus formation
ssociated with erosion rather than rupture (23).
arly Detection and Risk Stratification
onventional risk factors. The strengths and limitations
f novel biomarkers for risk stratification in comparison
rction (MI), or stroke in all patients with atherothrombosis and in subgroups
tt et al. (9).
ve been partially offset by obesity (2,3,5).
equent cardiovascular events (21).
fication in primary prevention (26).
ant serum biomarkers today (49).
isk factor control was estimated (74).
proved cardiovascular outcomes (89,92).
with clopidogrel (107–109).
dical therapy in more extensive and complex disease (110,111).
inal aortic atherothrombosis (114–117).ial infa
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Nonetheless, quantification of conventional risk factors
remains the mainstay of cardiovascular risk stratification and
the only class I indication in the setting of primary preven-
tion according to recent guidelines (26). As previously
shown for CHD, the INTERSTROKE study indicated
that 10 potentially modifiable factors account for most of
the risk of stroke worldwide (27). Growing evidence links
cardiovascular risk factors and vascular atherosclerosis not
only with stroke but also with loss of cognitive function
(28,29), expanding the clinical significance of this disease.
For those who achieve low LDL cholesterol levels, the
prognostic significance of other lipid fractions such as
HDL cholesterol may be more relevant to patients with
established CHD (30) than in the context of primary
prevention (31). An important study challenged the
notion that maintaining usual blood pressure within
targets is the optimal approach for hypertension manage-
ment, and demonstrated an independent role of systolic
blood pressure variability and instability in the prediction
of stroke and coronary events (Fig. 3) (32). According to
a large meta-analysis of 100 studies involving almost
00,000 subjects without previous disease, diabetes ap-
roximately doubles cardiovascular events independent of
ther risk factors, whereas impaired fasting glucose in-
reases risk only modestly (33). The REACH registry
eported lower rates of major cardiovascular events for
iabetic patients with risk factors than for nondiabetic
atients with established atherothrombotic disease, ques-
ioning the concept that diabetes mellitus should be
Figure 2 Neovascularization in Atherosclerosis
Microcomputed tomography of a coronary artery showing the lumen (red), calcified
Vasa vasorum (VV) (blue) are particularly increased in the noncalcified lesion. Reponsidered a CHD equivalent (9). Conversely, a historyof prior stroke seems to reflect a risk level (20% in 10
years) comparable to that of prior CHD (34).
Regarding clustering of risk factors, obesity and the
metabolic syndrome are often associated. A study involving
1,758 middle-aged men followed up for a median of 30
years demonstrated that each predicts incident cardiovascu-
lar disease in the absence of the other (35). A meta-analysis
of 950,000 patients found an approximately twofold
increase in cardiovascular events associated with the pres-
ence of the metabolic syndrome (36). The metabolic syn-
drome was also a predictor of myocardial infarction across
the world, although not beyond its individual components
(37). Comparable findings were reported in a meta-
analysis of 7 IVUS trials regarding the effects of the
metabolic syndrome on progression of coronary athero-
sclerosis (38).
Functional biomarkers. In 6,647 participants enrolled in
MESA (Multi-Ethnic Study of Atherosclerosis), the ankle-
brachial index was predictive of incident CHD, stroke, or
other atherosclerotic cardiovascular death independent of
traditional risk factors, serum biomarkers, electrocardio-
graphic abnormalities, the carotid intima-media thickness
(CIMT), and the coronary calcium score (39). In 2,232
participants of the Framingham Heart Study followed up
for a median of 7.8 years, arterial stiffness as reflected by
aortic pulse wave velocity was also associated with incident
major cardiovascular events after adjusting for standard risk
factors, including systolic blood pressure or history of
hypertension (40).
Serum biomarkers. The presence of diabetes is typically
es (yellow), and noncalcified plaques (transparent).
d, with permission, from Gossl et al. (20).plaqu
roducediagnosed from abnormal fasting glucose levels, whereas
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diagnosis. Nonetheless, data from 11,000 black and white
participants in the ARIC (Atherosclerosis Risk In Commu-
nities) study without known diabetes indicated that glycated
hemoglobin was a better predictor of death, CHD, and
stroke, particularly for concentrations 6%, than was fast-
ing glucose (41). The use and significance of C-reactive
protein (CRP) for risk stratification continued to be a
subject of intense debate during 2010. Data from the
Figure 3 Blood Pressure Variability and Outcome
The figure shows the hazard ratios for stroke (left column) and coronary events (r
(SBP) (upper row) or of variation independent of mean (VIM) SBP (lower row) in p
(142.8 mm Hg). Note the impaired outcome with increasing blood pressure varia
et al. (32). CI  confidence interval.Copenhagen City Heart Study suggested there is no casualrole of CRP in increased risk of mortality, but that it rather
represents a marker of underlying cardiovascular or noncar-
diovascular disease (42). A large meta-analysis of 54 pro-
spective studies including 160,000 participants without
evidence of cardiovascular disease reported continuous log-
linear associations between CRP and multiple vascular and
nonvascular outcomes. After adjusting for sex and conven-
tional risk factors, a 3-fold higher CRP concentration
resulted in increases in CHD, ischemic stroke, and vascular
olumn) according to deciles (red diamonds) of SD of systolic blood pressure
with an average SBP less than the median value for the trial population
despite (near) normal average SBP. Reproduced, with permission, from Rothwellight c
atients
bilitydeath ranging from 27% to 55% (43). Data from the ARIC
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risk when LDL cholesterol levels are low (130 mg/dl) and
CRP is elevated (2.0 mg/l) during a mean follow-up of
6.9 years, in comparison with the limited 1.9-year follow-up
in JUPITER (Justification for the Use of Statins in Primary
Prevention: An Intervention Trial Evaluating Rosuvasta-
tin), which was stopped early (44). An additional high-risk
subgroup may be that of persons with high HDL choles-
terol but elevated CRP (45).
A large meta-analysis of 40 prospective studies including
87,000 participants confirmed independent associations
between serum levels of brain natriuretic peptides and
incident cardiovascular disease (10,000 events) in a variety
of scenarios, including the general population, persons with
risk factors, and patients with known stable vascular disease.
These associations persisted after adjusting for conventional
risk factors, renal function, left ventricular ejection fraction,
or CRP, although improvements in risk discrimination
were, overall, modest (46). The significance of subclinical
myocardial necrosis as demonstrated with high-sensitivity
troponin assays was also addressed in several investigations.
In 3,679 patients with stable CHD and preserved left
ventricular function, plasma levels of troponin T well below
the limits of detection of standard assays showed a strong,
graded, and independent association with incident cardio-
vascular death (Fig. 4) and heart failure, but not myocardial
infarction (47). Similarly, baseline or newly elevated levels of
high-sensitivity troponin T were predictive of cardiovascular
death and heart failure in 4,221 elderly subjects followed up
for 11 years (48).
Importantly, with respect to multimarker approaches,
Figure 4 High-Sensitivity Cardiac Troponin T and Outcome
Incidence of cardiovascular death according to high-sensitivity cardiac troponin T concanother study evaluated 30 serum biomarkers in 10,000participants without established cardiovascular disease. No
single biomarker consistently improved 10-year risk strati-
fication above and beyond conventional risk factors, al-
though the authors proposed a composite “score” combining
brain natriuretic peptide, CRP, and sensitive troponin I
(49). Other novel biomarkers in cardiovascular disease were
reviewed elsewhere (50).
Genetic markers. The year 2010 witnessed a myriad of
studies addressing genetic variants associated with cardio-
vascular disease and, particularly, with response to therapy.
Recent reviews have addressed genetic markers in athero-
thrombosis in detail for the interested reader (51). Several
investigations addressed the potential of scores based on
allele carrier status or gene expression profiles to estimate
the likelihood of either incident cardiovascular events or
presence of obstructive CHD. These scores provided addi-
tive (although modest) information to conventional clinical
stratification in some studies (52,53) but not all (54). One of
the variants most consistently associated with CHD in-
volves the 9p21 gene, which was linked to increased
coronary atheroma burden both at early and late disease
stages (55). Conversely, reduced leukocyte telomere length
(a marker of cellular aging) was associated with advanced
(but not early) disease in 800 subjects observed prospectively
for 8 years (56).
In the field of pharmacogenetics, studies in 2010 ex-
tended prior evidence of an association of CYP2C19 and
ABCB1 loss-of-function variants with increased subsequent
events in patients treated with clopidogrel but not prasugrel,
maybe because of faster metabolic activation of the latter
(57). However, the clinical impact of these variants seems
n quartile (Q). Reproduced with permission from Omland et al. (47).entratiomore relevant in patients with an acute coronary syndrome
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subgroups remains uncertain (58). Conversely, the PLATO
(Platelet Inhibition and Patient Outcomes) study identified
no interactions between these genetic variants and treat-
ment effect of ticagrelor, an antiplatelet drug that does not
require metabolic activation (59).
Intravascular ultrasound. Pooled data from 6 clinical trials
that used serial IVUS in4,000 patients demonstrated that
baseline burden of coronary atherosclerosis as well as accel-
erated progression were independently associated with ma-
jor cardiovascular events (particularly revascularization) dur-
ing follow-up (60). Plaque progression was shown to occur
in 20% of patients who achieve LDL cholesterol levels
70 mg/dl. Baseline percent atheroma volume, diabetes
mellitus, increments in systolic blood pressure, inability to
raise HDL cholesterol, and smaller reductions in apolipo-
protein B levels were all associated with progression in this
setting (61). Another study of serial IVUS demonstrated the
highly dynamic nature of coronary atherosclerosis: during a
12-month interval, in symptomatic patients receiving con-
ventional medical therapies, as much as 75% of nonculprit
thin-cap fibroatheroma present at baseline transformed into
a more stable lesion type, whereas new thin-cap fibroathe-
roma developed (62). These findings could be of relevance
regarding risk stratification based on plaque features from a
single time point, or on lesion-targeted therapeutic
strategies.
Noninvasive imaging. Regarding imaging of subclinical
atherosclerosis with carotid ultrasound, data from the ARIC
study confirmed that adding the presence/absence of carotid
plaque to the quantification of CIMT improves prediction
of incident CHD (63). In experimental atherosclerosis,
contrast-enhanced ultrasonography was validated for the
noninvasive detection of plaque neovascularization (64). In
a cross-sectional study of patients with stroke or transient
ischemic attack imaged within 48 h of symptom onset, the
presence of ipsilateral type-VI carotid plaque as determined
by magnetic resonance imaging (characterized by large
necrotic cores, cap rupture, thrombus, or intraplaque hem-
orrhage) showed the strongest association with symptoms
after adjusting for the Framingham risk score, with an odds
ratio of 11.7 (95% CI: 5.3 to 25.6; p  0.0001) (65).
Several studies addressed the ability of coronary calcium
scoring for reclassification of risk category in asymptomatic
persons. The largest included 5,878 nondiabetic MESA
study participants followed up for a median of 5.8 years, in
whom addition of the calcium score to conventional strat-
ification improved coronary risk classification in 25% of the
subjects, particularly those in the intermediate category
(Fig. 5) (66). The prognostic value of coronary computed
tomography angiography was also revisited. Coronary com-
puted tomography was an independent predictor of cardiac
death and myocardial infarction in 2,000 mostly symp-
tomatic patients followed up for 16  8 months. Beyond
disease severity and left ventricular ejection fraction, a score
of plaque burden provided incremental prognostic informa-Figure 5 Risk Prediction With Coronary Calcification
Risk stratification of predictive models without coronary artery calcium score
(CACS), based on traditional risk factors (green bars), and adding CACS (blue
bars). Addition of the CACS places more patients who experienced events in the
high-risk category, and more patients who did not experience events in the low-risk
group. Reproduced, with permission, from Polonsky et al. (66). No.  number.
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myocardial infarction (67).
Molecular imaging. The evaluation of vascular inflamma-
tion with 18fluorodeoxyglucose positron emission tomogra-
hy was the central topic of several investigations. A study
f carotid positron emission tomography demonstrated
ncreased inflammatory activity in patients with impaired
asting glucose, and even higher in the presence of overt
iabetes. Moreover, tracer uptake progressed across Fra-
ingham risk categories (68). In a different in vivo inves-
igation, carotid inflammatory activity in symptomatic pa-
ients was associated with higher frequency of ipsilateral
rain microemboli (69). Using a different tracer that binds
enzodiazepine receptors expressed in activated macro-
hages, positron emission tomography could detect arterial
all inflammation in patients with vasculitis (70). Moving
nto experimental models of disease, magnetic resonance
maging allowed for the detection of intravascular thrombi
ith the use of a contrast agent targeted to activated
latelets (71). Spectral computed tomography, a technique
hat enables differentiation of various contrast agents in a
ingle scan based on their X-ray attenuation properties,
emonstrated potential for simultaneous depiction of arte-
ial inflammation (using a gold-HDL–based contrast agent
aken up by macrophages), intraluminal contrast, and cal-
ification (72). Another investigation demonstrated the
easibility of nonviral delivery, with the use of ultrasound
icrobubbles, of gene therapy aimed at inhibiting expres-
ion of intercellular adhesion molecule-1 in injured murine
rteries, resulting in successful suppression of neointimal
ormation (73).
revention and Treatment
he importance of prevention through lifestyle choices
annot be overemphasized. Interventions at the societal level
ould have enormous impact on public health. In the
ontext of high blood pressure, the most prevalent risk
actor, an intervention to reduce dietary salt consumption by
g/day (approximately by 30% to 50% of the usual intake)
as predicted to reduce cardiovascular events at least as
ffectively as other interventions targeting, for example,
obacco or obesity (Table 2) (74). Smoking cessation was
ssociated with 1-year improvements in endothelial func-
Projected Annual Reductions of Cardiovascularfor Various Popu ation InterventionsTable 2 Project Annual Reducti ns of Cafor Various Population Interventions
Intervention
Salt reduction (3 g/day)–low-high estimates
Smoking cessation (by 50%)
Weight reduction (5% reduction in body mass index of obes
Statin therapy for primary prevention (10-yr CHD risk 20%
Pharmacologic therapy for hypertension
Values are percent reduction.
CHD  coronary heart disease; MI  myocardial infarction.ion despite weight gain (75). A study examining differ- mnt diets reported that weight loss maintained for a
-year period can induce regression of carotid atheroscle-
osis, probably through associated reductions in blood
ressure (76). However, dietary supplements of omega-3
atty acids failed to reduce subsequent cardiovascular
vents among myocardial infarction survivors in large
andomized trials (77).
yslipidemia and statin therapy. Statins continue to be
he mainstay of medical therapy for atherothrombosis. A
eta-analysis of nearly 170,000 participants supported in-
ensive statin therapy by confirming that protection from
yocardial infarction and ischemic stroke is directly pro-
ortional to the absolute LDL level reductions, with no
vidence of a threshold below which these benefits are lost
78). Statin benefits seem to come at the expense of a small
isk (odds ratio: 1.09; 95% CI: 1.02 to 1.17) of increased
ncidence of diabetes according to another meta-analysis of
3 controlled trials (79). In the setting of primary preven-
ion and regarding the use of an approach like that of the
UPITER study in the community, it was reported that
tatin initiation at lower risk without CRP testing would be
ore cost effective than measuring CRP levels, assuming
hat statins provide benefit in the absence of increased CRP
80). In the presence of moderate kidney disease, rosuvas-
atin therapy still improves outcomes, according to a sec-
ndary analysis of the JUPITER trial (81). In line with
hese findings, but in contrast with prior randomized studies
hat failed to demonstrate benefit of statin therapy on
ialysis patients, interesting results came from SHARP
Study of Heart And Renal Protection). The SHARP trial
valuated the combination of simvastatin and ezetimibe in
,500 adults with moderate to severe chronic kidney disease
one-third were on dialysis). After a median follow-up of
.9 years, patients randomly assigned to the drug combina-
ion experienced a 17% reduction in major atherothrom-
otic events compared with the placebo group (p  0.0021)
82). These findings question the prior failure of simvasta-
in/ezetimibe to reduce surrogates of cardiovascular disease
uch as the CIMT.
High-density lipoprotein cholesterol as a therapeutic
arget was revisited in 2010. A meta-analysis of 18 placebo-
ontrolled trials and 45,000 participants reported that
brates are associated with a 10% relative risk reduction of
tscular Events
CHD MI Stroke Mortality
5.9–9.6 7.6–12.0 5.0–7.8 2.6–4.1
3.7 11.9 4.4 4.3
ts) 5.3 8.0 0.7 2.0
5.3 2.9 0.9 0.3
9.3 13.1 9.3 4.9Evenrdiova
e adul
)ajor cardiovascular events, driven mainly by a 13% reduc-
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shown to increase not only HDL concentrations but also its
endothelial-protective properties in diabetic patients (84).
Two large prospective cohorts reported associations be-
tween reduced cholesteryl ester transfer protein (CETP)
levels or activity with impaired cardiovascular outcomes,
challenging the concept of CETP inhibition as a cardiopro-
tective pharmacologic approach (85,86). Although this no-
tion might be supported by the previous failure of torce-
trapib, which caused increases in both blood pressure and
mortality, the novel CETP inhibitor anacetrapib was tested
in 1,623 patients with known CHD or high cardiovascular
risk receiving statins. In comparison with placebo, anac-
etrapib lowered LDL cholesterol by 39.8%, lipoprotein(a)
by 36.4%, and increased HDL cholesterol by 138.1%,
without increases in blood pressure, aldosterone levels, or
identifiable adverse events during 18 months (87). It re-
mains to be proven if these favorable lipid changes translate
into improved outcomes. In a feasibility study, infusing
autologous delipidated HDL after an acute coronary syn-
drome was shown to markedly increase concentrations of
pre–-like HDL, resulting in nonsignificant reductions in
coronary atheroma volume (88).
Diabetes mellitus. Because of the higher baseline cardio-
vascular risk associated with diabetes, it has been largely
hypothesized that tighter metabolic control could improve
outcomes in this setting. However, prior studies failed to
clearly demonstrate reductions in macrovascular events with
intensive glucose-lowering approaches, maybe because of
higher incidence of hypoglycemia (89). In addition, the risks
associated with intensive glucose lowering seem to be
especially relevant in patients with more advanced disease as
reflected by higher hemoglobin A1c concentrations (Fig. 6)
(90). Several investigations published last year did not
support the use of more intensive lipid or antihypertensive
therapy either. A substudy of the ACCORD (Action to
Control Cardiovascular Risk in Diabetes) study randomly
assigned 5,518 patients with type 2 diabetes with and
without cardiovascular disease to simvastatin plus either
placebo or fenofibrate. After an average of 4.7 years of
follow-up and despite significant increases in HDL and
reductions in triglycerides levels, no benefit was observed in
terms of major cardiovascular events (HR: 0.95, 95% CI:
0.79 to 1.08; p  0.32) or any of the secondary outcomes
(91). Another substudy of the same trial enrolling 4,733
patients with the same follow-up compared intensive anti-
hypertensive therapy to a target systolic pressure 120 mm
Hg versus the standard of 140 mm Hg. Despite an
average systolic blood pressure of 119.3 mm Hg in the
intensive arm (vs. 133.5 mm Hg in the standard arm), there
were no significant reductions in major events (Fig. 7). The
rates of stroke were reduced in the intensive-therapy arm,
although at the cost of an increase in serious side effects
(92). Similar lack of benefit was reported in a secondary
analysis according to blood pressure achieved in another
large trial: among 6,400 diabetic patients, those whoreached a systolic pressure130 mm Hg did not experience
improved outcomes and, in fact, an increase in all-cause
mortality was noted (93). These findings may reflect differ-
ent susceptibility of various organs to lower perfusion
pressure in the setting of diabetic arteriopathy (94). Regard-
ing the optimal antihypertensive agent in diabetes, data
from the ACCOMPLISH (Avoiding Cardiovascular
Events Through Combination Therapy in Patients Living
With Systolic Hypertension) study supported the addition
of a calcium-channel blocker (amlodipine) as opposed to a
diuretic (hydrochlorothiazide) to an angiotensin-converting
enzyme inhibitor because of reduced cardiovascular events
(95). Conversely, the use of valsartan versus placebo in
patients with impaired glucose tolerance and established
cardiovascular disease or cardiovascular risk factors for a
median of 5 years reduced the incidence of diabetes but not
cardiovascular events in the NAVIGATOR (Nateglinide
and Valsartan in Impaired Glucose Tolerance Outcomes
Research) study (96).
The controversy regarding cardiovascular safety of com-
mon oral glucose-lowering agents, specifically thiazolidin-
ediones, continued in 2010. As a result, the American Heart
Association and American College of Cardiology Founda-
tion issued a Scientific Advisory recommending that these
drugs should not be expected to reduce cardiovascular
disease, that they should be avoided for patients in func-
tional class III/IV as they increase the risk of heart failure,
and that there are insufficient data to support the choice of
pioglitazone over rosiglitazone (97). Nonetheless, in a
nationwide evaluation of 227,571 elderly Medicare benefi-
ciaries, rosiglitazone increased the risk of stroke, heart
failure, and all-cause mortality, but not myocardial infarc-
tion, in comparison with pioglitazone, although this was a
retrospective analysis (98). In the setting of impaired glu-
cose tolerance, the short-acting insulin secretagogue nat-
eglinide was also tested in the NAVIGATOR study,
leading to no reductions in either incident diabetes or
cardiovascular events in comparison with placebo (99).
Drug therapy for weight loss. After the withdrawal from
the market of cannabinoid-1 receptor-blocker rimonobant
because of safety concerns, new agents for weight loss were
tested in 2010. The norepinephrine and serotonin reuptake
inhibitor sibutramine was associated with higher rates of
nonfatal cardiovascular events but not mortality among
high-risk obese patients, particularly those with known
cardiovascular disease (100). More promising results were
reported with the daily use of the serotonin 2C-receptor
agonist lorcaserin. In comparison with placebo, it led to
maintained although modest reductions in weight with
improvements in cardiovascular risk factors and good safety
profile over 2 years (101).
Antithrombotic therapy. The role of aspirin for primary
prevention continued to be a matter of debate. In particular,
there are certain clinical scenarios with intrinsically higher
cardiovascular risk where the use of aspirin was evaluated. In
the context of diabetes, a joint statement of the American
787JACC Vol. 58, No. 8, 2011 Sanz and Fuster
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American Diabetes Association recommended considering
low-dose aspirin (75 to 165 mg/day) for diabetic patients
with an estimated 10-year cardiovascular risk 10% (102).
In patients with peripheral artery disease, the Aspirin for
Figure 6 Standard Versus Intensive Glucose Lowering in Type 2
Hazard ratios (and 95% confidence intervals) of all-cause mortality in the ACCORD
hemoglobin A1C from 6.0% to 9.0%. Intensive therapy is associated with increased
patients with advanced diabetes may be poorer candidates for intensive glucose l
Figure 7 Standard Versus Intensive Blood Pressure
Control in Type 2 Diabetes
Cumulative incidence curves for the primary composite of nonfatal myocardial
infarction, nonfatal stroke, or cardiovascular death according to blood pressure
control arm. Reproduced, with permission, from Cushman et al. (92).Asymptomatic Atherosclerosis trial randomly allocated
3,350 asymptomatic participants with low ankle-brachial
index (0.95) to receive placebo or aspirin 100 mg once
daily. After a mean follow-up of 8.2 years, there was no
significant reduction in cardiovascular events but a trend for
increased bleeding (103). Conversely, a post-hoc analysis of
a large trial of hypertensive patients mostly free from
cardiovascular disease showed that, in the presence of
chronic kidney disease, low-dose aspirin (75 mg daily)
provided a significant net beneficial effect that appeared
more pronounced for those with more severe reductions in
glomerular filtration rate (104).
Regarding thienopyridines, concern exists of a potential
interaction between clopidogrel and protease pump inhibi-
tors, which also inhibit the cytochrome P450 isoenzyme
CYP2C19. This was addressed in a trial that randomly
assigned 3,761 patients to dual antiaggregation therapy with
aspirin and clopidogrel plus either omeprazole or placebo.
Omeprazol reduced gastrointestinal bleeding by at least
70%, without evidence of increased cardiovascular events.
These results should be interpreted with caution in view
of the limited follow-up (median 108 days) (105). Data
from TRITON–TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhi-
bition With Prasugrel–Thrombolysis In Myocardial In-
farction 38) suggested that a strategy using prasugrel in
etes According to Baseline Hemoglobin A1C
n to Control Cardiovascular Risk in Diabetes) study within the range of average
ality in patients with higher baseline levels of hemoglobin A1C, suggesting that
g. Reproduced, with permission, from Riddle et al. (90).Diab
(Actio
mort
owerinlieu of clopidogrel for up to 15 months (particularly in the
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acute coronary syndrome undergoing percutaneous coro-
nary intervention (106). Also in this group of patients, a
subanalysis of the PLATO study reinforced the clinical
superiority of ticagrelor with a reduction in the combination
of cardiovascular death, myocardial infarction, or stroke
(HR: 0.84, 95% CI: 0.75 to 0.94; p  0.0025) without
increases in bleeding complications (107). In addition,
studies showed that ticagrelor provides greater and more
consistent platelet inhibition than clopidogrel, and once
approved for clinical use, it might be considered as an
alternative for clopidogrel nonresponders (108,109).
Stable CHD. Several studies addressed different therapeu-
tic strategies for patients with stable multivessel CHD and
confirmed that, in general, surgery outperforms percutane-
ous revascularization in more complex disease (i.e., higher
SYNTAX [The SYNergy between PCI with TAXUS and
Cardiac Surgery] score) and when subsequent revasculariza-
tion is included as an outcome. In the 10-year follow-up
report of MASS II (Second Medical, Angioplasty, or
Surgery Study), which enrolled patients with stable angina,
multivessel disease, and preserved ventricular function who
were good candidates for all 3 therapies, surgical revascu-
larization reduced the incidence of combined mortality,
infarction, or refractory angina requiring revascularization in
comparison with percutaneous intervention (HR: 0.53, 95%
CI: 0.39 to 0.72; p  0.001) or medical therapy (HR: 0.43,
95% CI: 0.32 to 0.58; p  0.001) (110). In diabetic patients
treated with aggressive medical therapy in the BARI 2D
(Bypass Angioplasty Revascularization Investigation 2 Di-
abetes) trial, prompt revascularization provided increased
protection against myocardial infarction (particularly if
combined with insulin-sensitizing therapy) only when sur-
gery was deemed the optimal revascularization approach,
typically in patients with more extensive disease. Five-year
outcomes were similar for medical therapy or percutaneous
revascularization in patients with less complex disease (111).
Moreover, in this patient subset, a strategy of intensive
medical therapy followed by delayed revascularization if
clinically indicated was found to be cost effective (112). In
addition, the previously reported benefits in mortality and
myocardial infarction of percutaneous revascularization
guided by fractional flow reserve as opposed to angiographic
lesion severity were extended up to 2 years in a report from
the FAME (Fractional Flow Reserve Versus Angiography
for Multivessel Evaluation) study (113).
Peripheral atherothrombosis. Several relevant studies
compared outcomes after surgical versus percutaneous in-
tervention in peripheral arterial disease. The multicenter
CREST (Carotid Revascularization Endarterectomy vs.
Stenting Trial) randomly allocated 2,502 patients with
symptomatic or asymptomatic carotid stenosis amenable for
both surgical and percutaneous repair to undergo carotid
endarterectomy or stenting, and observed them for a median
of 2.5 years (114). There was no significant difference in
long-term outcome as evaluated by the combination ofperiprocedural stroke, myocardial infarction, or death, or
long-term stroke (HR with stenting: 1.11; 95% CI: 0.81 to
1.51; p  0.51). Endarterectomy was associated with more
periprocedural myocardial infarction and stenting with more
periprocedural strokes (reported to have a stronger impact
on quality of life). However, short-term follow-up data from
the ICSS (International Carotid Stenting Study) indicated
increased incidence of stroke, death, or procedural myocar-
dial infarction with stenting (HR: 1.69, 95% CI: 1.16 to
2.45; p  0.006) and supported surgery as the current
therapy of choice (115). Similarly, a meta-analysis of 3
different trials concluded that endarterectomy is associated
with better outcomes than stenting, particularly for patients
70 years of age (116).
Regarding the treatment of abdominal aortic aneurysms,
endovascular repair (stenting) has been associated with
decreased perioperative mortality in comparison with sur-
gery. The EVAR (Endovascular Aneurysm Repair) trial
presented long-term (median 6 years) follow-up data on
1,252 patients with aneurysms 5.5 cm in diameter and a
mean age of 74 years who were randomly assigned to either
stenting or surgical repair. The initial 6-month benefits of
stenting were lost subsequently, with no differences in
overall mortality at 2 years or in aneurysm-related death at
6 years. In addition, stenting was associated with higher
costs (117). Among patients ineligible for surgical repair,
aneurysm-related mortality, but not overall survival, was
reduced with stenting versus medical therapy, again at the
expense of increased costs (118).
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